IDH1 and acute myeloid leukemia: The phase III AGILE trial for newly diagnosed IDH1‐mutated AML ineligible for intensive induction chemotherapy showed the combination of ivosidenib and azacitidine was superior to placebo and azacitidine in terms of EFS (HR, 0.33; p = 0.002) and OS (median OS: 24.0 vs. 7.9 months; HR, 0.44; 95%CI: 0.27, 0.73; p = 0.001).